FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295477360> ?p ?o ?g. }

• W4295477360 endingPage "e0274115" @default.
• W4295477360 startingPage "e0274115" @default.
• W4295477360 abstract "Once a drug gets FDA approved, researchers often attempt to discover new applications in different indications. The clinical impact of such post-approval activities is uncertain. We aimed to compare the clinical impact of research efforts started after approval with those started before for cancer drugs.We used Drugs@FDA to perform a retrospective cohort study of secondary approvals for cancer drugs that were initially FDA approved between 2005 and 2017. Clinicaltrials.gov was used to identify the beginning of each research trajectory that resulted in a secondary FDA approval. Each trajectory was classified as pre- or post-approval depending on if it was initiated before or after initial drug licensure. Clinical impact was assessed by comparing secondary approvals and NCCN off-label recommendations deriving from pre- vs. post-approval trajectories, pooled effect sizes, incidence, and level of evidence.We identified 77 broad secondary approvals, 60 of which had at least 6 years follow-up. Of these, 9 (15%) resulted from post-approval trajectories, a proportion that is significantly lower than would be expected if the timing of research didn't impact approval (McNemar's test p = 0.001). Compared to pre-approval trajectories, approvals resulting from post-approval trajectories were for cancers with lower mean incidence (6.11 vs 14.83, p = 0.006) and were based on pivotal trials with smaller pooled effect sizes (0.69 vs 0.57, p = 0.02) that were less likely to be randomized (38.5% vs 64.1%, p = 0.145). We identified 69 NCCN off-label recommendations. The proportion stemming from post-approval trajectories was similar to that for pre-approval (56.5% vs. 43.5%). However, recommendations from post-approval trajectories were significantly more likely to involve rare diseases (76.7% vs 51.4%, p = 0.019) and nonsignificantly less likely to be based on level 1 evidence (11.6% vs 22.9%, p = 0.309).Secondary FDA approvals are less likely to result from post-approval trajectories and tend to be less impactful compared to approvals originating from research started before first FDA licensure. However, post-approval trajectories may be as likely to lead to NCCN recommendations for off-label use. Limitations of this work include our use of indirect measures of impact and limited follow-up time for trajectories. Our study protocol was pre-registered (https://osf.io/5g3jw/)." @default.
• W4295477360 created "2022-09-14" @default.
• W4295477360 creator A5075892804 @default.
• W4295477360 creator A5082034251 @default.
• W4295477360 creator A5086766678 @default.
• W4295477360 date "2022-09-12" @default.
• W4295477360 modified "2023-10-06" @default.
• W4295477360 title "Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study" @default.
• W4295477360 cites W1598602811 @default.
• W4295477360 cites W1599854648 @default.
• W4295477360 cites W1859631792 @default.
• W4295477360 cites W2118820600 @default.
• W4295477360 cites W2126438085 @default.
• W4295477360 cites W2127887787 @default.
• W4295477360 cites W2135796724 @default.
• W4295477360 cites W2138652650 @default.
• W4295477360 cites W2147959998 @default.
• W4295477360 cites W2148666312 @default.
• W4295477360 cites W2163692077 @default.
• W4295477360 cites W2182442935 @default.
• W4295477360 cites W2340197727 @default.
• W4295477360 cites W2426866456 @default.
• W4295477360 cites W2619666607 @default.
• W4295477360 cites W2754725540 @default.
• W4295477360 cites W2760938773 @default.
• W4295477360 cites W2765587792 @default.
• W4295477360 cites W2793971788 @default.
• W4295477360 cites W2896002881 @default.
• W4295477360 cites W2977977580 @default.
• W4295477360 cites W2991412921 @default.
• W4295477360 cites W3008358016 @default.
• W4295477360 cites W3022755254 @default.
• W4295477360 cites W3043204261 @default.
• W4295477360 cites W3118556611 @default.
• W4295477360 cites W3161904500 @default.
• W4295477360 cites W4225602258 @default.
• W4295477360 cites W3004655333 @default.
• W4295477360 doi "https://doi.org/10.1371/journal.pone.0274115" @default.
• W4295477360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36094914" @default.
• W4295477360 hasPublicationYear "2022" @default.
• W4295477360 type Work @default.
• W4295477360 citedByCount "1" @default.
• W4295477360 countsByYear W42954773602023 @default.
• W4295477360 crossrefType "journal-article" @default.
• W4295477360 hasAuthorship W4295477360A5075892804 @default.
• W4295477360 hasAuthorship W4295477360A5082034251 @default.
• W4295477360 hasAuthorship W4295477360A5086766678 @default.
• W4295477360 hasBestOaLocation W42954773601 @default.
• W4295477360 hasConcept C105795698 @default.
• W4295477360 hasConcept C120665830 @default.
• W4295477360 hasConcept C121332964 @default.
• W4295477360 hasConcept C121608353 @default.
• W4295477360 hasConcept C126322002 @default.
• W4295477360 hasConcept C141071460 @default.
• W4295477360 hasConcept C159110408 @default.
• W4295477360 hasConcept C167135981 @default.
• W4295477360 hasConcept C186282968 @default.
• W4295477360 hasConcept C2777106319 @default.
• W4295477360 hasConcept C2780035454 @default.
• W4295477360 hasConcept C2781234862 @default.
• W4295477360 hasConcept C2992293740 @default.
• W4295477360 hasConcept C3020340455 @default.
• W4295477360 hasConcept C33923547 @default.
• W4295477360 hasConcept C502991105 @default.
• W4295477360 hasConcept C535046627 @default.
• W4295477360 hasConcept C61511704 @default.
• W4295477360 hasConcept C71924100 @default.
• W4295477360 hasConcept C72563966 @default.
• W4295477360 hasConcept C98274493 @default.
• W4295477360 hasConceptScore W4295477360C105795698 @default.
• W4295477360 hasConceptScore W4295477360C120665830 @default.
• W4295477360 hasConceptScore W4295477360C121332964 @default.
• W4295477360 hasConceptScore W4295477360C121608353 @default.
• W4295477360 hasConceptScore W4295477360C126322002 @default.
• W4295477360 hasConceptScore W4295477360C141071460 @default.
• W4295477360 hasConceptScore W4295477360C159110408 @default.
• W4295477360 hasConceptScore W4295477360C167135981 @default.
• W4295477360 hasConceptScore W4295477360C186282968 @default.
• W4295477360 hasConceptScore W4295477360C2777106319 @default.
• W4295477360 hasConceptScore W4295477360C2780035454 @default.
• W4295477360 hasConceptScore W4295477360C2781234862 @default.
• W4295477360 hasConceptScore W4295477360C2992293740 @default.
• W4295477360 hasConceptScore W4295477360C3020340455 @default.
• W4295477360 hasConceptScore W4295477360C33923547 @default.
• W4295477360 hasConceptScore W4295477360C502991105 @default.
• W4295477360 hasConceptScore W4295477360C535046627 @default.
• W4295477360 hasConceptScore W4295477360C61511704 @default.
• W4295477360 hasConceptScore W4295477360C71924100 @default.
• W4295477360 hasConceptScore W4295477360C72563966 @default.
• W4295477360 hasConceptScore W4295477360C98274493 @default.
• W4295477360 hasFunder F4320334506 @default.
• W4295477360 hasIssue "9" @default.
• W4295477360 hasLocation W42954773601 @default.
• W4295477360 hasLocation W42954773602 @default.
• W4295477360 hasLocation W42954773603 @default.
• W4295477360 hasLocation W42954773604 @default.
• W4295477360 hasOpenAccess W4295477360 @default.
• W4295477360 hasPrimaryLocation W42954773601 @default.

• next